ORTHO-NOVUM 7/7/7-21
LOE ApproachingNDAORAL-21TABLET
Approved
Apr 1984
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 7/7/7-21 is an oral contraceptive tablet containing norethindrone and ethinyl estradiol in a triphasic formulation designed to reduce hormone exposure while maintaining efficacy. It is indicated for pregnancy prevention in women of reproductive age. The product works through suppression of ovulation via combined hormonal mechanisms.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), indicating mature market dynamics and likely focus on loyalty and cost management rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited career growth given its mature, LOE-approaching lifecycle and zero linked job openings in the current market. Roles available would focus on defensive brand management, payer negotiations, and regulatory compliance rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on ORTHO-NOVUM 7/7/7-21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.